| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA937: Targeted-release budesonide for treating primary IgA nephropathy |
|
Medicine details |
|
| Medicine name | budesonide (Kinpeygo®) |
| Formulation | capsule |
| Reference number | 3908 |
| Indication | Treatment of primary immunoglobulin A (IgA) nephropathy (IgAN) in adults at risk of rapid disease progression with a urine protein-to-creatinine ratio (UPCR) ≥1.5 g/gram |
| Company | Cadila Healthcare Ltd |
| BNF chapter | Malignant disease & immunosuppression |
| Assessment type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 08/07/2022 |
| NICE guidance | TA937: Targeted-release budesonide for treating primary IgA nephropathy |